Log In

Forgot Password?


Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Insomnia and Post Acute Sequelae of COVID-19 in an outpatient neurology cohort
P1 - Poster Session 1 (8:00 AM-9:00 AM)
 Insomnia may be a symptom that patients with Post-acute COVID-19 sequelae (PASC) experience. 

This study aimed to evaluate levels of insomnia in a cohort of PASC patients. 


This study analyzed symptoms of 93 SARS-CoV-2 positive patients who were recruited from an outpatient neurology clinic. During an initial baseline assessment and at a 1-year-follow up, standardized assessment scales were used during a phone interview. The Insomnia Severity Index is a validated tool to assess insomnia symptoms. Among the 42 patients that completed the follow-up, symptoms between the initial and 1-year follow-up evaluation were compared.

At baseline, 51% of participants reported difficulty sleeping, compared to 48% at follow-up. Of follow-up participants, 47% reported no clinically significant insomnia, 33% reported subthreshold insomnia, 16% reported moderate clinical insomnia, and 5% reported severe clinical insomnia. Of people who reported difficulty sleeping (n=20), 11 (55%) had no insomnia or subthreshold insomnia, and 9 scored in the moderate to severe range on the ISI scale. Difficulty sleeping at baseline evaluation was not associated with ISI scores at the follow-up visit. Binary ISI (scores less than 15 = no or subthreshold insomnia or greater than 15=moderate to severe insomnia) was associated with Neuro-QOL anxiety t-score (p=0.034, logistic regression adjusting for age, gender, race/ethnicity), fatigue t-score (p=0.009), depression t-score (p=0.023) and MOCA score (p=0.048). Binary ISI was not associated with HIT6 or number of headaches in the last 30 days on the AMPP questionnaire.


Sleep disturbances may be an important symptom which may be overlooked in patients suffering from PASC, which can be ongoing and disruptive for periods of years. Furthermore, association with worsened quality-of-life measures for depression, fatigue, and anxiety make this area of PASC one that warrants further attention.
Sherry Fung (NYU Langone)
Ms. Fung has nothing to disclose.
Rachel Kenney Rachel Kenney has nothing to disclose.
Sara Wesley Hyman (new york university) Ms. Hyman has nothing to disclose.
Azizi Seixas Azizi Seixas has nothing to disclose.
Girardin Jean-Louis No disclosure on file
Laura J. Balcer, MD, MSCE, FAAN (NYU Grossman School of Medicine) An immediate family member of Dr. Balcer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Children's Hospital of Philadelphia. Dr. Balcer has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for North American Neuro-Ophthalmology Society.
Sujata P. Thawani, MD (NYU Neurology Associates) Dr. Thawani has nothing to disclose.